Oral allosteric TYK2 inhibitor

Deucravacitinib

Brand names: Sotyktu

Deucravacitinib is an oral selective tyrosine kinase 2 (TYK2) inhibitor used for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits TYK2 by binding its regulatory domain, dampening signalling of interleukin-23, interleukin-12 and type I interferons that drive psoriatic inflammation.

Prescribing in practice

Screen for and exclude active serious infection including tuberculosis before starting, as immunomodulation increases infection risk.
Avoid live vaccines during treatment and ensure vaccinations are up to date beforehand.
Assess for response within the expected timeframe and review continuation against agreed treatment targets.

Monitoring

Monitor for signs of infection and review for other class-relevant effects in line with the SPC during treatment.

Counselling the patient

This is a tablet taken once daily for psoriasis; take it as prescribed.
Report fevers or other signs of infection promptly.
Tell your clinician you are on this medicine before having any vaccinations.

Evidence & guidelines

Deucravacitinib is recommended by NICE as an option for moderate to severe plaque psoriasis, supported by the POETYK PSO phase 3 trials.

Reference: NICE TA907; BAD psoriasis; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways